US 12221422
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted A61KA61K31/513A61K9/0053
Quick answer
US patent 12221422 (Compounds and their use for the treatment of alpha1-antitrypsin deficiency) held by CENTESSA PHARMACEUTICALS (UK) LIMITED expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CENTESSA PHARMACEUTICALS (UK) LIMITED
- Grant date
- Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/513, A61K9/0053, A61P, A61P1/16